One of the FDA’s potential approvals this month could break an existing monopoly in the treatment space for a rare growth ...

In its most recent quarterly report, Genmab A/S posted strong results, with third quarter sales reaching US$1.02 billion and net income more than doubling compared to a year earlier. The company also ...

Media Release COPENHAGEN, Denmark; November 10, 2025 Genmab A/S (“Genmab”) announced on November 10, 2025, that it and its wholly owned subsidiary Genmab Finance LLC intend to offer, subject to market ...

Media Release COPENHAGEN, Denmark; November 10, 2025 Genmab A/S (Nasdaq: GMAB) (“Genmab”) announced today that it and its wholly owned subsidiary Genmab Finance LLC (“Genmab Finance”) intend to offer, ...

Fintel reports that on November 10, 2025, HC Wainwright & Co. maintained coverage of Genmab A (NasdaqGS:GMAB) with a Buy recommendation. Analyst Price Forecast Suggests 117.15% Upside As of November 9 ...

Danish biotech Genmab reported a 25% rise in its total revenue to $1.02 billion during the third quarter of 2025, ahead of ...

November 6, 2025 Copenhagen, Denmark; Interim Report for the Nine Months Ended September 30, 2025 Highlights Announcement of Genmab's proposed acquisition of Merus N.V. (Merus)Genmab revenue increased ...

Genmab revenue increased 21% compared to the first nine months of 2024, to $2,662 million FDA granted BTD to Rina-S ® in advanced endometrial cancer Epcoritamab Phase 3 EPCORE ® FL-1 trial met dual ...

Genmab ( ($GMAB) ) has issued an announcement. On November 6, 2025, Genmab announced its financial results for the first nine months of 2025, ...

Media ReleaseCOPENHAGEN, Denmark; November 5, 2025Genmab A/S (Nasdaq: GMAB) announced today that its Chief Executive Officer Jan Van de Winkel and Chief Financial Officer Anthony Pagano will ...

Genmab A/S(Nasdaq: GMAB)today announced that more than 20 abstracts evaluating epcoritamab-bysp, a T-cell engaging bispecific antibody administered subcutaneously, across lines of therapy and B-cell ...

Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline includes ...